stockrow
Friday 6 November 2026
Export ADAPY’s income statement to Excel — free account
Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024.
- Revenue
- −89.3%
- EPS
- −140.7%
- Free cash flow
- −174.7%
Quarter to June 2025, against a year earlier
0.02
0.00
0.00%
Follow ADAPY
Alert me
| Older periods | Dec '24 | Mar '25 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
0.77 | 0.29 | 0.97 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(3.98) | (0.77) | (1.82) | — | |
P/B ratio |
10.45 | 0.00 | 0.00 | — | |
Price to Tangible BV |
30.18 | 0.00 | 0.00 | — | |
EV/Sales |
0.20 | 0.10 | 0.97 | — | |
EV/EBITDA |
4.44 | 1.57 | 0.00 | — | |
EV/Operating CF |
(0.48) | (0.16) | (0.33) | — | |
EV/FCF |
(0.46) | (0.16) | (0.33) | — | |
Quick Ratio |
2.56 | 1.25 | 0.69 | — | |
Current Ratio |
2.88 | 2.02 | 1.52 | — | |
Net Debt/EBITDA |
19.15 | 0.79 | 0.01 | — | |
Debt/Assets |
20.39% | 16.08% | 19.65% | 0.00% | |
Debt/Equity |
4.24 | (0.68) | (0.36) | — | |
Asset Turnover |
0.67 | 0.86 | 0.29 | 0.00 | |
Operating CF/Net income |
0.45 | 1.40 | 1.15 | — | |
Capex/Depreciation |
(0.05) | (0.49) | (0.03) | — | |
Interest Coverage |
(38.02) | (24.31) | (31.48) | — | |
Research and Development Expense of Revenue |
51.96% | 396.12% | 168.01% | — | |
Selling, General and Administrative Expense of Revenue |
204.75% | 319.59% | 135.15% | — | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.03 | 0.00 | |
Share Based Compensation of Revenue |
53.01% | 9.18% | 9.66% | — | |
Graham Net Nets |
(0.34) | (1.80) | (1.95) | — | |
Graham Number |
0.00 | 0.94 | 1.98 | — | |
Earnings Yield |
(50.00%) | (135.00%) | (270.83%) | — | |
Free Cash Flow Yield |
(55.13%) | (215.64%) | (304.01%) | — | |
Revenue per Share |
0.01 | 0.03 | 0.05 | — | |
Operating CF per Share |
(0.14) | (0.26) | (0.13) | — | |
Capex per Share |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(0.14) | (0.26) | (0.13) | — | |
Cash per Share |
0.60 | 0.23 | 0.10 | — | |
Shareholders Equity per Share |
0.05 | (0.15) | (0.27) | — | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
0.05 | (0.15) | (0.27) | — | |
Free Cash Flow |
(34.56) | (67.79) | (34.85) | — | |
Working Capital |
122.19 | 51.93 | 26.60 | — | |
Capital Expenditures |
(0.36) | (1.20) | (0.07) | — | |
Net Current Asset Value |
(46.34) | (92.50) | (123.48) | — | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.11 | 0.17 | 0.01 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
7.60 | 6.39 | 5.82 | — | |
Average Payables |
24.56 | 6.14 | 8.47 | — | |
Average Assets |
264.52 | 208.04 | 226.17 | 158.72 | |
Average Common Equity |
26.27 | (6.53) | 12.66 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026